Skip to main content
SpringerLink
Log in
Book cover

Neuroendocrine Tumours pp 233–250Cite as

Glucagonoma

  • Chapter

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. McGavran MH, Unger RH, Recant L et al (1966) A glucagon-secreting alpha-cell carcinoma of the pancreas. N Engl J Med 274:1408–1413

    Google Scholar 

  2. Solcia EKG, Sobin LH, World Health Organization (2000) Histological typing of endocrine tumors, 2nd edn, International histological classification of tumors. Springer, Berlin, pp 56–58

    Google Scholar 

  3. Becker ER (1942) The Iowa Academy of Science. Science 95:651–652

    Google Scholar 

  4. Mallinson CN, Bloom SR, Warin AP et al (1974) A glucagonoma syndrome. Lancet 2:1–5

    Google Scholar 

  5. Wilkinson DS (1984) Necrolytic migratory erythema: glucagonoma syndrome. Clinical and histological aspects. Ann Med Interne (Paris) 135:654–657

    Google Scholar 

  6. Kufe DW, Pollock RE, Weichselbaum RR, Bast RC, Gansler TS, Holland JF, Frei E (2003) Cancer medicine, 4th edn. BC Decker, Hamilton, pp 1289–1290

    Google Scholar 

  7. Sheaves RJP, Wass JAH (1997) Clinical endocrine oncology, 1st edn. Blackwell Science, Oxford, pp 380–382, 387–390

    Google Scholar 

  8. Furlan D, Cerutti R, Uccella S et al (2004) Different molecular profiles characterize well-differentiated endocrine tumors and poorly differentiated endocrine carcinomas of the gastroenteropancreatic tract. Clin Cancer Res 10:947–957

    Google Scholar 

  9. DeGroot LJ, Jameson JL (2001) Endocrinology, 4th edn. W.B Saunders, Philadelphia, p 2506

    Google Scholar 

  10. Yamada TAD, Owyang C, Powell DW, Silverstein EF (2003) Textbook of gastroenterology, 4th edn. Lippincott Williams and Wilkins, Philadelphia, pp 2115–2117

    Google Scholar 

  11. Sleisenger MH, Fordtran JS (2002) Gastrointestinal diseases. W:B: Saunders Company, Philadelphia, pp 994–997

    Google Scholar 

  12. Rosai J (2004) Surgical pathology. Mosby, London, pp 1088–1089

    Google Scholar 

  13. Case CC, Vassilopoulou-Sellin R (2003) Reproduction of features of the glucagonoma syndrome with continuous intravenous glucagon infusion as therapy for tumor-induced hypoglycemia. Endocr Pract 9:22–25

    Google Scholar 

  14. Soga J, Yakuwa Y (1998) Glucagonomas/diabetico-dermatogenic syndrome (DDS): a statistical evaluation of 407 reported cases. J Hepatobiliary Pancreat Surg 5:312–319

    Google Scholar 

  15. Alexander EK, Robinson M, Staniec M et al (2002) Peripheral amino acid and fatty acid infusion for the treatment of necrolytic migratory erythema in the glucagonoma syndrome. Clin Endocrinol (Oxf) 57:827–831

    Google Scholar 

  16. Wermers RA, Fatourechi V, Wynne AG et al (1996) The glucagonoma syndrome. Clinical and pathologic features in 21 patients. Medicine (Baltimore) 75:53–63

    Google Scholar 

  17. Boden G (1989) Glucagonomas and insulinomas. Gastroenterol Clin North Am 18:831–845

    Google Scholar 

  18. Stacpoole PW (1981) The glucagonoma syndrome: clinical features, diagnosis, and treatment. Endocr Rev 2:347–361

    Google Scholar 

  19. Chang-Chretien K, Chew JT, Judge DP (2004) Reversible dilated cardiomyopathy associated with glucagonoma. Heart 90:e44

    Google Scholar 

  20. Eriksson B, Oberg K, Stridsberg M (2000) Tumor markers in neuroendocrine tumors. Digestion 62(Suppl 1):33–38

    Google Scholar 

  21. Anderson MA, Carpenter S, Thompson NW et al (2000) Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas. Am J Gastroenterol 95:2271–2277

    Google Scholar 

  22. Briganti V, Matteini M, Ferri P et al (2001) Octreoscan SPET evaluation in the diagnosis of pancreas neuroendocrine tumors. Cancer Biother Radiopharm 16:515–524

    Google Scholar 

  23. Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (2010) AJCC cancer staging handbook, 7th edn. Springer, New York

    Google Scholar 

  24. Bilimoria KY, Bentrem DJ, Merkow RP et al (2007) Application of the pancreatic adenocarcinoma staging system to pancreatic neuroendocrine tumors. J Am Coll Surg 205:558–563

    Google Scholar 

  25. Phan GQ, Yeo CJ, Hruban RH et al (1998) Surgical experience with pancreatic and peripancreatic neuroendocrine tumors: review of 125 patients. J Gastrointest Surg 2:473–482

    Google Scholar 

  26. Oberg K, Casanovas O, Castano JP et al (2013) Molecular pathogenesis of neuroendocrine tumors: implications for current and future therapeutic approaches. Clin Cancer Res 19:2842–2849

    Google Scholar 

  27. Missiaglia E, Dalai I, Barbi S et al (2010) Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol 28:245–255

    Google Scholar 

  28. Zhang J, Francois R, Iyer R et al (2013) Current understanding of the molecular biology of pancreatic neuroendocrine tumors. J Natl Cancer Inst 105:1005–1017

    Google Scholar 

  29. Kulke MH, Lenz HJ, Meropol NJ et al (2008) Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 26:3403–3410

    Google Scholar 

  30. Raymond E, Dahan L, Raoul JL et al (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364:501–513

    Google Scholar 

  31. Yao JC, Lombard-Bohas C, Baudin E et al (2010) Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 28:69–76

    Google Scholar 

  32. Yao JC, Shah MH, Ito T et al (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364:514–523

    Google Scholar 

  33. Contessa JN, Griffith KA, Wolff E et al (2009) Radiotherapy for pancreatic neuroendocrine tumors. Int J Radiat Oncol Biol Phys 75:1196–1200

    Google Scholar 

  34. Strosberg J, Hoffe S, Gardner N et al (2007) Effective treatment of locally advanced endocrine tumors of the pancreas with chemoradiotherapy. Neuroendocrinology 85:216–220

    Google Scholar 

  35. Tennvall J, Ljungberg O, Ahren B et al (1992) Radiotherapy for unresectable endocrine pancreatic carcinomas. Eur J Surg Oncol 18:73–76

    Google Scholar 

  36. Torrisi JR, Treat J, Zeman R et al (1987) Radiotherapy in the management of pancreatic islet cell tumors. Cancer 60:1226–1231

    Google Scholar 

  37. Keskin O, Yalcin S (2013) A review of the use of somatostatin analogs in oncology. Onco Targets Ther 6:471–483

    Google Scholar 

  38. Tomassetti P, Migliori M, Corinaldesi R et al (2000) Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR. Aliment Pharmacol Ther 14:557–560

    Google Scholar 

  39. Arnold R, Wied M, Behr TH (2002) Somatostatin analogues in the treatment of endocrine tumors of the gastrointestinal tract. Expert Opin Pharmacother 3:643–656

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Cancer Institute, Hacettepe University, Sihhiye, Ankara, Turkey

    Suayib Yalcin

  2. Department of Pathology, School of Medicine, Hacettepe University, Ankara, Turkey

    Cenk Sokmensuer

  3. Department of Medical Oncology, Hacettepe University Institute of Cancer, Ankara, Turkey

    Ece Esin

Authors
  1. Suayib Yalcin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cenk Sokmensuer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ece Esin
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey

    Suayib Yalcin

  2. Department of Endocrine Oncology, Uppsala University Hospital, Uppsala, Sweden

    Kjell Öberg

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Yalcin, S., Sokmensuer, C., Esin, E. (2015). Glucagonoma. In: Yalcin, S., Öberg, K. (eds) Neuroendocrine Tumours. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-45215-8_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-45215-8_15

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-45214-1

  • Online ISBN: 978-3-662-45215-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation